Skip to main content
Top
Published in: Drugs & Aging 8/2004

01-07-2004 | Therapy In Practice

Hypoglycaemia in Elderly Patients with Diabetes Mellitus

Causes and Strategies for Prevention

Authors: Aruna Chelliah, Dr Mark R. Burge

Published in: Drugs & Aging | Issue 8/2004

Login to get access

Abstract

Achieving target glycaemic goals while avoiding hypoglycaemia is a major challenge in the management of elderly patients with diabetes mellitus. Repeated episodes of hypoglycaemia may cause extreme emotional distress in such patients, even when the episodes are relatively mild. Moreover, evidence is mounting that hypoglycaemia among elderly patients is a very real and costly health concern. The strongest predictors of severe hypoglycaemia in the elderly are advanced age, recent hospitalisation and polypharmacy. Education is the key to preventing recurrent or severe hypoglycaemia. As such, there should be close coordination of care between the patient, physician and all other healthcare providers in identifying the cause of hypoglycaemia in elderly patients, and appropriate steps should be taken to prevent further episodes. Prevention of hypoglycaemia has the potential to improve psychosocial aspects of elderly health, including enhanced quality of life, boosted confidence, improved compliance with antidiabetic regimens and avoidance of long-term complications.
Since the elderly population represents a unique group, it is imperative to focus on the aetiologies that are exclusive to this group. Advanced age itself is a risk factor for hypoglycaemia, and elderly patients with comorbidities are at increased risk when they are hospitalised. Elderly patients with diabetes often have compromised renal function, which intereferes with drug elimination and thus predisposes them to prolonged life-threatening hypoglycaemia. In addition, patients on five or more prescription medications are prone to drug-associated hypoglycaemia. Although sulfonylurea-associated hypoglycaemia is common, drugs such as ACE inhibitors and nonselective β-adrenoceptor antagonists can also predispose patients to hypoglycaemia. Greater attention should be paid to the avoidance of hypgolycaemia in nursing home residents. Recurrent hypoglycaemia in elderly patients is not only detrimental to achieving good glycaemic control, it is also a substantial economic burden.
Once the causes of hypoglycaemia have been identified, it is crucial to formulate and institute a prevention plan. Firstly, global evaluation of the patient should be carried out to identify possible predisposing risk factors. Secondly, target glycaemic goals should be tailored to each patient. Thirdly, selection of antidiabetic agents should be judicious, then patients and family should be educated to recognise and treat hypoglycaemia. Finally, coordinated care should be provided to identify, treat and prevent hypoglycaemia.
Literature
1.
go back to reference Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993; 16(4): 642–52PubMed Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993; 16(4): 642–52PubMed
2.
go back to reference Harris MI. Epidemiological correlates of NIDDM in Hispanic, Whites and Blacks in the US population. Diabetes Care 1991; 14(7): 639–48PubMedCrossRef Harris MI. Epidemiological correlates of NIDDM in Hispanic, Whites and Blacks in the US population. Diabetes Care 1991; 14(7): 639–48PubMedCrossRef
3.
go back to reference Rockwood K, Await E, MacKnight C, et al. Incidence and outcomes of diabetes mellitus in elderly people: report from the Canadian study of health and aging. CMAJ 2000; 162(6): 769–72PubMed Rockwood K, Await E, MacKnight C, et al. Incidence and outcomes of diabetes mellitus in elderly people: report from the Canadian study of health and aging. CMAJ 2000; 162(6): 769–72PubMed
4.
go back to reference Teuscher AU, Reinli K, Teuscher A. Prevalence of diabetes mellitus and impaired glucose in elderly European subjects. Diabetes 1999; 48Suppl. 1: 395–6 Teuscher AU, Reinli K, Teuscher A. Prevalence of diabetes mellitus and impaired glucose in elderly European subjects. Diabetes 1999; 48Suppl. 1: 395–6
5.
go back to reference Bertoni AG, Krop JS, Anderson GF, et al. Diabetes-related morbidity and mortality in a national sample of US elders. Diabetes Care 2002; 25: 471–5PubMedCrossRef Bertoni AG, Krop JS, Anderson GF, et al. Diabetes-related morbidity and mortality in a national sample of US elders. Diabetes Care 2002; 25: 471–5PubMedCrossRef
6.
go back to reference Krop JS, Powe NR, Weller WE, et al. Patterns of expenditures and use of services among older adults with diabetes: implications for transition to capitated managed care. Diabetes Care 1998; 21: 747–52PubMedCrossRef Krop JS, Powe NR, Weller WE, et al. Patterns of expenditures and use of services among older adults with diabetes: implications for transition to capitated managed care. Diabetes Care 1998; 21: 747–52PubMedCrossRef
7.
go back to reference Holstein A, Plaschke A, Egberts EH. Incidence and costs of severe hypoglycemia. Diabetes Care 2002; 25: 2109–10PubMedCrossRef Holstein A, Plaschke A, Egberts EH. Incidence and costs of severe hypoglycemia. Diabetes Care 2002; 25: 2109–10PubMedCrossRef
8.
go back to reference The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977–86 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977–86
9.
go back to reference The UKPDS Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53CrossRef The UKPDS Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53CrossRef
10.
go back to reference Cryer PE, Gerich JE. Hypoglycemia in insulin-dependent diabetes mellitus: interplay of insulin excess and compromised glucose counterregulation. In: Porte D, Sherwin RS, editors. Ellenburg and Rifkin’s diabetes mellitus: theory and practice. 5th ed. Stamford (CT); Appleton and Lange, 1997: 745–60 Cryer PE, Gerich JE. Hypoglycemia in insulin-dependent diabetes mellitus: interplay of insulin excess and compromised glucose counterregulation. In: Porte D, Sherwin RS, editors. Ellenburg and Rifkin’s diabetes mellitus: theory and practice. 5th ed. Stamford (CT); Appleton and Lange, 1997: 745–60
11.
go back to reference Herbei G, Boyle PJ. Hypoglycemia: pathophysiology and treatment. Endocrinol Metab Clin N Am 2000; 29: 725–43CrossRef Herbei G, Boyle PJ. Hypoglycemia: pathophysiology and treatment. Endocrinol Metab Clin N Am 2000; 29: 725–43CrossRef
12.
go back to reference Pardridge WM. Brain metabolism: a perspective from the blood-brain barrier. Physiol Rev 1983; 63(4): 1481–535PubMed Pardridge WM. Brain metabolism: a perspective from the blood-brain barrier. Physiol Rev 1983; 63(4): 1481–535PubMed
13.
go back to reference Pardridge WM, Boado RJ, Farrell CR. Brain-type glucose transporter (GLUT-1) is selectively localized to the blood brain barrier: studies with quantitative western blotting and in situ hybridization. J Biol Chem 1990; 265: 18035–40PubMed Pardridge WM, Boado RJ, Farrell CR. Brain-type glucose transporter (GLUT-1) is selectively localized to the blood brain barrier: studies with quantitative western blotting and in situ hybridization. J Biol Chem 1990; 265: 18035–40PubMed
14.
go back to reference Borg MA, Sherwin RS, Borg WP, et al. Local ventromedial hypothalamus glucose perfusion blocks counterregulation during systemic hypoglycemia in awake rats. J Clin Invest 1997; 99(2): 361–5PubMedCrossRef Borg MA, Sherwin RS, Borg WP, et al. Local ventromedial hypothalamus glucose perfusion blocks counterregulation during systemic hypoglycemia in awake rats. J Clin Invest 1997; 99(2): 361–5PubMedCrossRef
15.
go back to reference Borg WP, During MJ, Sherwin RS, et al. Ventromedial hypothalamus lesions in rats suppress counterregulatory hormone responses to hypoglycemia. J Clin Invest 1994; 93(4): 1677–82PubMedCrossRef Borg WP, During MJ, Sherwin RS, et al. Ventromedial hypothalamus lesions in rats suppress counterregulatory hormone responses to hypoglycemia. J Clin Invest 1994; 93(4): 1677–82PubMedCrossRef
16.
go back to reference Borg WP, Sherwin RS, During MJ, et al. Local ventromedial hypothalamus glycopenia triggers counterregulatory hormone release. Diabetes 1995; 44(2): 180–4PubMedCrossRef Borg WP, Sherwin RS, During MJ, et al. Local ventromedial hypothalamus glycopenia triggers counterregulatory hormone release. Diabetes 1995; 44(2): 180–4PubMedCrossRef
17.
go back to reference Cryer PE. Glucose counterregulation: prevention and correction of hypoglycemia in humans. Am J Physiol 1993; 264 (2 Pt 1): E149–55PubMed Cryer PE. Glucose counterregulation: prevention and correction of hypoglycemia in humans. Am J Physiol 1993; 264 (2 Pt 1): E149–55PubMed
18.
go back to reference Rizza RA, Mandarino LJ, Gerich JE. Dose-response characteristics for the effects of insulin on production and utilization of glucose in man. Am J Physiol 1981; 240: E630–9PubMed Rizza RA, Mandarino LJ, Gerich JE. Dose-response characteristics for the effects of insulin on production and utilization of glucose in man. Am J Physiol 1981; 240: E630–9PubMed
19.
go back to reference Schwartz NS, Clutter WE, Shah SD, et al. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest 1987; 79: 777–81PubMedCrossRef Schwartz NS, Clutter WE, Shah SD, et al. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest 1987; 79: 777–81PubMedCrossRef
20.
go back to reference Heller SR, Cryer PE. Hypoinsulinemia is not critical to glucose recovery from hypoglycemia in humans. Am J Physiol 1991; 261: E41–8PubMed Heller SR, Cryer PE. Hypoinsulinemia is not critical to glucose recovery from hypoglycemia in humans. Am J Physiol 1991; 261: E41–8PubMed
21.
go back to reference Gerich J, Davis J, Lorenzi M, et al. Hormonal mechanisms of recovery from insulin induced hypoglycemia in man. Am J Physiol 1979; 236: E380–5PubMed Gerich J, Davis J, Lorenzi M, et al. Hormonal mechanisms of recovery from insulin induced hypoglycemia in man. Am J Physiol 1979; 236: E380–5PubMed
22.
go back to reference Rizza R, Cryer PE, Gerich JE. Role of glucagon, epinephrine and growth hormone in human glucose counterregulation: effects of somatostatin and adrenergic blockade on plasma glucose recovery and glucose flux rates following insulin induced hypoglycemia. J Clin Invest 1979; 64: 62–71PubMedCrossRef Rizza R, Cryer PE, Gerich JE. Role of glucagon, epinephrine and growth hormone in human glucose counterregulation: effects of somatostatin and adrenergic blockade on plasma glucose recovery and glucose flux rates following insulin induced hypoglycemia. J Clin Invest 1979; 64: 62–71PubMedCrossRef
23.
go back to reference Rizza RA, Cryer PE, Haymond MW, et al. Adrenergic mechanisms for the effect of epinephrine on glucose production and clearance in man. J Clin Invest 1980; 65: 682–9PubMedCrossRef Rizza RA, Cryer PE, Haymond MW, et al. Adrenergic mechanisms for the effect of epinephrine on glucose production and clearance in man. J Clin Invest 1980; 65: 682–9PubMedCrossRef
24.
go back to reference Rizza RA, Cryer PE, Haymond MW, et al. Differential effects of physiological concentration of epinephrine on glucose production and disposal in man. Am J Physiol 1979; 237: E356–62PubMed Rizza RA, Cryer PE, Haymond MW, et al. Differential effects of physiological concentration of epinephrine on glucose production and disposal in man. Am J Physiol 1979; 237: E356–62PubMed
25.
go back to reference White NH, Skor DA, Cryer PE, et al. Identification of type 1 diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med 1983; 308: 485–91PubMedCrossRef White NH, Skor DA, Cryer PE, et al. Identification of type 1 diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med 1983; 308: 485–91PubMedCrossRef
26.
go back to reference Bolli GB, DeFeo P, DeCosmo S, et al. A reliable and reproducible test for adequate glucose counterregulation in type 1 diabetes mellitus. J Clin Invest 1985; 75: 1623–31PubMedCrossRef Bolli GB, DeFeo P, DeCosmo S, et al. A reliable and reproducible test for adequate glucose counterregulation in type 1 diabetes mellitus. J Clin Invest 1985; 75: 1623–31PubMedCrossRef
27.
go back to reference Caprio S, Gelfand RA, Tamborlane WV, et al. Oxidative fuel metabolism during mild hypoglycemia: critical role of free fatty acids. Am J Physiol Endocrinol Metab 1989; 256: E413–9 Caprio S, Gelfand RA, Tamborlane WV, et al. Oxidative fuel metabolism during mild hypoglycemia: critical role of free fatty acids. Am J Physiol Endocrinol Metab 1989; 256: E413–9
28.
go back to reference Fanelli CG, De Feo P, Porcellati F, et al. Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis. Clin Invest 1992; 89(6): 2005–13CrossRef Fanelli CG, De Feo P, Porcellati F, et al. Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis. Clin Invest 1992; 89(6): 2005–13CrossRef
29.
go back to reference Boyle PJ, Cryer PE. Growth hormone, Cortisol, or both are involved in defense against, but are not critical to recovery from, hypoglycemia. Am J Physiol 1991; 260: E395–402PubMed Boyle PJ, Cryer PE. Growth hormone, Cortisol, or both are involved in defense against, but are not critical to recovery from, hypoglycemia. Am J Physiol 1991; 260: E395–402PubMed
30.
go back to reference Mitrakou A, Ryan C, Veneman T, et al. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol 1991; 260: E67–74PubMed Mitrakou A, Ryan C, Veneman T, et al. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol 1991; 260: E67–74PubMed
31.
go back to reference Bolli GB, DeFeo P, Perriello G, et al. Role of hepatic autoregulation in defense against hypoglycemia in humans. J Clin Invest 1985; 75: 1623–31PubMedCrossRef Bolli GB, DeFeo P, Perriello G, et al. Role of hepatic autoregulation in defense against hypoglycemia in humans. J Clin Invest 1985; 75: 1623–31PubMedCrossRef
32.
go back to reference Hansen I, Firth R, Haymond M, et al. The role of autoregulation of hepatic glucose production in man: response to a physiologic decrements in plasma glucose. Diabetes 1986; 35: 186–91PubMedCrossRef Hansen I, Firth R, Haymond M, et al. The role of autoregulation of hepatic glucose production in man: response to a physiologic decrements in plasma glucose. Diabetes 1986; 35: 186–91PubMedCrossRef
33.
go back to reference Campbell PJ, Bolli GB, Cryer PE, et al. Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus: accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion. N Engl J Med 1985; 312(23): 1473–9PubMedCrossRef Campbell PJ, Bolli GB, Cryer PE, et al. Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus: accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion. N Engl J Med 1985; 312(23): 1473–9PubMedCrossRef
34.
go back to reference Somogyi M. Insulin as a cause of extreme hyperglycemia and instability. Bull St Louis Med Soc 1938; 32: 498–501 Somogyi M. Insulin as a cause of extreme hyperglycemia and instability. Bull St Louis Med Soc 1938; 32: 498–501
35.
go back to reference Bolli GB, Gottesman IS, Campbell PJ, et al. Glucose counterregulation and waning of insulin in the Somogyi phenomenon (posthypoglycemic hyperglycemia). N Engl J Med 1984; 311(19): 1214–9PubMedCrossRef Bolli GB, Gottesman IS, Campbell PJ, et al. Glucose counterregulation and waning of insulin in the Somogyi phenomenon (posthypoglycemic hyperglycemia). N Engl J Med 1984; 311(19): 1214–9PubMedCrossRef
36.
go back to reference Kollind M. Studies on posthypoglycemic insulin resistance in insulin-dependent diabetes mellitus. Acta Med Scand Suppl 1988; 727: 1–56PubMed Kollind M. Studies on posthypoglycemic insulin resistance in insulin-dependent diabetes mellitus. Acta Med Scand Suppl 1988; 727: 1–56PubMed
37.
go back to reference Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157: 1681–6PubMedCrossRef Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157: 1681–6PubMedCrossRef
39.
go back to reference Seltzer HS. Drug-induced hypoglycemia: a review of 1418 cases. Endocrinol Metab Clin North Am 1989; 18: 163–83PubMed Seltzer HS. Drug-induced hypoglycemia: a review of 1418 cases. Endocrinol Metab Clin North Am 1989; 18: 163–83PubMed
40.
go back to reference Casparie AF, Elving LD. Severe hypoglycemia in diabetic patients: frequency, causes, prevention. Diabetes Care 1985; 8: 141–5PubMedCrossRef Casparie AF, Elving LD. Severe hypoglycemia in diabetic patients: frequency, causes, prevention. Diabetes Care 1985; 8: 141–5PubMedCrossRef
41.
go back to reference Fertig BJ, Simmons DA, Martin DB. Therapy for diabetes. In: Harris MI, Cowie CC, Stern MP, et al., editors. Diabetes in America. 2nd ed. Bethesda (MD): DHHS (NIH), 1995; Publication no. 95–1468: 519–40 Fertig BJ, Simmons DA, Martin DB. Therapy for diabetes. In: Harris MI, Cowie CC, Stern MP, et al., editors. Diabetes in America. 2nd ed. Bethesda (MD): DHHS (NIH), 1995; Publication no. 95–1468: 519–40
43.
go back to reference Wiholm BE, Westerholm B. Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden. Acta Med Scand Suppl 1984; 683: 107–17PubMed Wiholm BE, Westerholm B. Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden. Acta Med Scand Suppl 1984; 683: 107–17PubMed
44.
go back to reference Berger W. Incidence of severe side effects during therapy with sulfonylureas and biguanides. Hormone Metab Res 1985; 17Suppl. 15: 111–5 Berger W. Incidence of severe side effects during therapy with sulfonylureas and biguanides. Hormone Metab Res 1985; 17Suppl. 15: 111–5
45.
go back to reference Campbell IW. Metformin and the sulfonylureas: the comparative risk. Horm Metab Res 1985; 17Suppl. 15: 105–11 Campbell IW. Metformin and the sulfonylureas: the comparative risk. Horm Metab Res 1985; 17Suppl. 15: 105–11
46.
go back to reference Van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997; 50: 735–41PubMedCrossRef Van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997; 50: 735–41PubMedCrossRef
47.
go back to reference Shorr RI, Ray WA, Daugherty JR, et al. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 1996; 44: 751–5PubMed Shorr RI, Ray WA, Daugherty JR, et al. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 1996; 44: 751–5PubMed
48.
go back to reference Stahl M, Berger W. Higher incidence of severe hypoglycemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulfonylureas. Diabet Med 1999; 16: 586–90PubMedCrossRef Stahl M, Berger W. Higher incidence of severe hypoglycemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulfonylureas. Diabet Med 1999; 16: 586–90PubMedCrossRef
49.
go back to reference Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycaemia in NIDDM patients treated with oral hypoglycaemic agents. Diabetes Care 1989; 12: 203–8PubMedCrossRef Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycaemia in NIDDM patients treated with oral hypoglycaemic agents. Diabetes Care 1989; 12: 203–8PubMedCrossRef
50.
go back to reference Burge MR, Schmitz-Fiorentino K, Fischette C, et al. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. JAMA 1998; 279: 137–43PubMedCrossRef Burge MR, Schmitz-Fiorentino K, Fischette C, et al. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. JAMA 1998; 279: 137–43PubMedCrossRef
51.
go back to reference Walter MW. Hypoglycemia: still a risk in the elderly. Geriatrics 1990; 45: 69–75PubMed Walter MW. Hypoglycemia: still a risk in the elderly. Geriatrics 1990; 45: 69–75PubMed
52.
go back to reference Brodows RG. Benefits and risks with glyburide and glipizide in elderly NIDDM patients. Diabetes Care 1992; 15: 75–80PubMedCrossRef Brodows RG. Benefits and risks with glyburide and glipizide in elderly NIDDM patients. Diabetes Care 1992; 15: 75–80PubMedCrossRef
53.
go back to reference Heinsmer JA, Lefowitz RJ. The impact of aging and adrenergic receptor function: clinical and biochemical aspects. J Am Geriatr Soc 1985; 33: 184–8 Heinsmer JA, Lefowitz RJ. The impact of aging and adrenergic receptor function: clinical and biochemical aspects. J Am Geriatr Soc 1985; 33: 184–8
54.
go back to reference Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type a diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317: 713–20 Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type a diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317: 713–20
55.
go back to reference Shorr RI, Wayne AR, Daugherty JR, et al. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997; 278: 40–3PubMedCrossRef Shorr RI, Wayne AR, Daugherty JR, et al. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997; 278: 40–3PubMedCrossRef
56.
go back to reference Herings RM, de Boer A, Stricker BH, et al. Hypoglycemia associated with use of inhibitors of angiotensin-converting enzymes. Lancet 1995; 345: 1195–8PubMedCrossRef Herings RM, de Boer A, Stricker BH, et al. Hypoglycemia associated with use of inhibitors of angiotensin-converting enzymes. Lancet 1995; 345: 1195–8PubMedCrossRef
57.
go back to reference Rasmussen BM, Orskov L, Schmitz O, et al. Alcohol and glucose counterregulation during acute insulin induced hypoglycemia in type 2 diabetes subjects. Metabolism 2001; 50: 451–7PubMedCrossRef Rasmussen BM, Orskov L, Schmitz O, et al. Alcohol and glucose counterregulation during acute insulin induced hypoglycemia in type 2 diabetes subjects. Metabolism 2001; 50: 451–7PubMedCrossRef
58.
go back to reference Burge MR, Zeise TM, Sobhy TA, et al. Low dose ethanol predisposes elderly fasted patients with type 2 diabetes to sulfonylurea-induced low blood glucose. Diabetes Care 1999; 22: 2037–43PubMedCrossRef Burge MR, Zeise TM, Sobhy TA, et al. Low dose ethanol predisposes elderly fasted patients with type 2 diabetes to sulfonylurea-induced low blood glucose. Diabetes Care 1999; 22: 2037–43PubMedCrossRef
59.
go back to reference Sood V, Sobhy TA, Schade DS, et al. Low dose ethanol delays recovery from hypoglycemia in type 2 diabetes [abstract]. Diabetes 2000; 49Suppl. 1: A66 Sood V, Sobhy TA, Schade DS, et al. Low dose ethanol delays recovery from hypoglycemia in type 2 diabetes [abstract]. Diabetes 2000; 49Suppl. 1: A66
60.
go back to reference Sood V, Sobhy T, Schade DS, et al. Low dose ethanol alters epinephrine responses and decreases glucose production during hypoglycemia in patients with type 2 diabetes [abstract]. Diabetes 2001; 50Suppl. 1: A139 Sood V, Sobhy T, Schade DS, et al. Low dose ethanol alters epinephrine responses and decreases glucose production during hypoglycemia in patients with type 2 diabetes [abstract]. Diabetes 2001; 50Suppl. 1: A139
61.
go back to reference Riddle MC, McDaniel PA, Tive LA. Glipizide GITS does not increase the hypoglycemic effect of mild exercise during fasting in NIDDM. Diabetes Care 1997; 20: 992–4PubMedCrossRef Riddle MC, McDaniel PA, Tive LA. Glipizide GITS does not increase the hypoglycemic effect of mild exercise during fasting in NIDDM. Diabetes Care 1997; 20: 992–4PubMedCrossRef
62.
go back to reference Katz MS, Lowenthal DT. Influences of age and exercise on glucose metabolism: implications for management of older diabetics. South Med J 1994; 87: S70–3PubMed Katz MS, Lowenthal DT. Influences of age and exercise on glucose metabolism: implications for management of older diabetics. South Med J 1994; 87: S70–3PubMed
63.
go back to reference Gerich JE, Langlois M, Noacco C, et al. Lack of glucagons response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science 1973; 182: 171–3PubMedCrossRef Gerich JE, Langlois M, Noacco C, et al. Lack of glucagons response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science 1973; 182: 171–3PubMedCrossRef
64.
go back to reference Fukuda M, Tanaka A, Tahara Y, et al. Correlation between minimal secretory capacity of pancreatic beta-cells and stability of diabetic control. Diabetes 1988; 37: 81–8PubMedCrossRef Fukuda M, Tanaka A, Tahara Y, et al. Correlation between minimal secretory capacity of pancreatic beta-cells and stability of diabetic control. Diabetes 1988; 37: 81–8PubMedCrossRef
65.
go back to reference Robertson RP, Porte Jr D. The glucose receptor: a defective mechanism in diabetes mellitus distinct from the beta-adrenergic receptor. J Clin Invest 1973; 52: 870–6PubMedCrossRef Robertson RP, Porte Jr D. The glucose receptor: a defective mechanism in diabetes mellitus distinct from the beta-adrenergic receptor. J Clin Invest 1973; 52: 870–6PubMedCrossRef
66.
go back to reference Meneilly GS, Cheung E, Tuokko H. Altered response to hypoglycemia of healthy elderly people. J Clin Endocrinol Metab 1994; 78: 1341–8PubMedCrossRef Meneilly GS, Cheung E, Tuokko H. Altered response to hypoglycemia of healthy elderly people. J Clin Endocrinol Metab 1994; 78: 1341–8PubMedCrossRef
67.
go back to reference Marker JC, Cryer PE, Clutter WE. Attenuated glucose recovery from hypoglycemia in the elderly. Diabetes 1992; 41: 671–8PubMedCrossRef Marker JC, Cryer PE, Clutter WE. Attenuated glucose recovery from hypoglycemia in the elderly. Diabetes 1992; 41: 671–8PubMedCrossRef
68.
go back to reference Meneilly GS, Cheung E, Tuokko H. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes 1994; 43: 403–10PubMedCrossRef Meneilly GS, Cheung E, Tuokko H. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes 1994; 43: 403–10PubMedCrossRef
69.
go back to reference Segel SA, Deanna SP, Paramore S, et al. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 2002; 51: 724–33PubMedCrossRef Segel SA, Deanna SP, Paramore S, et al. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 2002; 51: 724–33PubMedCrossRef
70.
go back to reference Korzon-Burakowska A, Hopkins D, Matyka K, et al. Effects of glycemic control on protective responses against hypoglycemia in type 2 diabetes. Diabetes Care 1998; 21: 283–90PubMedCrossRef Korzon-Burakowska A, Hopkins D, Matyka K, et al. Effects of glycemic control on protective responses against hypoglycemia in type 2 diabetes. Diabetes Care 1998; 21: 283–90PubMedCrossRef
71.
go back to reference Burge MR, Sobhy TA, Quails CR, et al. Effect of short-term glucose control on glycemic thresholds for epinephrine and hypoglycemic symptoms. J Clin Endocrinol Metab 2001; 86: 5471–8PubMedCrossRef Burge MR, Sobhy TA, Quails CR, et al. Effect of short-term glucose control on glycemic thresholds for epinephrine and hypoglycemic symptoms. J Clin Endocrinol Metab 2001; 86: 5471–8PubMedCrossRef
72.
go back to reference Mokan M, Mitrakou A, Veneman T, et al. Hypoglycemia unawareness in IDDM. Diabetes Care 1994; 17: 1397–403PubMedCrossRef Mokan M, Mitrakou A, Veneman T, et al. Hypoglycemia unawareness in IDDM. Diabetes Care 1994; 17: 1397–403PubMedCrossRef
73.
go back to reference Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994; 17: 697–703PubMedCrossRef Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994; 17: 697–703PubMedCrossRef
74.
go back to reference Veneman T, Mitrakou A, Mokan M, et al. Induction of hypoglycemia unawareness by symptomatic nocturnal hypoglycemia. Diabetes 1993; 42: 1233–7PubMedCrossRef Veneman T, Mitrakou A, Mokan M, et al. Induction of hypoglycemia unawareness by symptomatic nocturnal hypoglycemia. Diabetes 1993; 42: 1233–7PubMedCrossRef
75.
go back to reference Thomson FJ, Masson EA, Leeming JT, et al. Lack of knowledge of symptoms of hypoglycemia by elderly diabetic patients. Age Ageing 1991; 20: 404–6PubMedCrossRef Thomson FJ, Masson EA, Leeming JT, et al. Lack of knowledge of symptoms of hypoglycemia by elderly diabetic patients. Age Ageing 1991; 20: 404–6PubMedCrossRef
76.
go back to reference Schillinger D, Grumbach K, Piette J, et al. Association of health literacy with diabetes mellitus. JAMA 2002; 288: 475–82PubMedCrossRef Schillinger D, Grumbach K, Piette J, et al. Association of health literacy with diabetes mellitus. JAMA 2002; 288: 475–82PubMedCrossRef
77.
go back to reference Colleran KM, Starr B, Burge MR. Putting diabetes to the test: analyzing glycemic control based on patients’ diabetes knowledge. Diabetes Care 2003; 26: 2220–1PubMedCrossRef Colleran KM, Starr B, Burge MR. Putting diabetes to the test: analyzing glycemic control based on patients’ diabetes knowledge. Diabetes Care 2003; 26: 2220–1PubMedCrossRef
78.
go back to reference Rabasa-Lhoret R, Bourque J, Ducros F, et al. Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro). Diabetes Care 2001; 24(4): 625–30PubMedCrossRef Rabasa-Lhoret R, Bourque J, Ducros F, et al. Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro). Diabetes Care 2001; 24(4): 625–30PubMedCrossRef
79.
go back to reference Rosenstock J, Shen GS, Gatlin MR, et al. Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care 2002; 25: 1529–33PubMedCrossRef Rosenstock J, Shen GS, Gatlin MR, et al. Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care 2002; 25: 1529–33PubMedCrossRef
80.
go back to reference Saloranta C, Kenneth H, Ball M, et al. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab 2002; 87: 4171–6PubMedCrossRef Saloranta C, Kenneth H, Ball M, et al. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab 2002; 87: 4171–6PubMedCrossRef
81.
go back to reference Frische A, Schweitzer MA, Häring HU, et al. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. Ann Intern Med 2003; 138: 952–9 Frische A, Schweitzer MA, Häring HU, et al. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. Ann Intern Med 2003; 138: 952–9
82.
go back to reference Yki-Jarvinen H, Dressier A, Ziemen M, et al. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000; 23: 1130–6PubMedCrossRef Yki-Jarvinen H, Dressier A, Ziemen M, et al. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000; 23: 1130–6PubMedCrossRef
83.
go back to reference Cooper WC. Fatal asymptomatic hypoglycemia in an elderly insulin-dependent diabetic patient taking an oral beta-blocking medication. Diabetes Care 1998; 21: 2197–8PubMedCrossRef Cooper WC. Fatal asymptomatic hypoglycemia in an elderly insulin-dependent diabetic patient taking an oral beta-blocking medication. Diabetes Care 1998; 21: 2197–8PubMedCrossRef
84.
go back to reference Fischer KF, Lees JA, Newman JH. Hypoglycemia in hospitalized patients. N Engl J Med 1986; 315: 1245–50PubMedCrossRef Fischer KF, Lees JA, Newman JH. Hypoglycemia in hospitalized patients. N Engl J Med 1986; 315: 1245–50PubMedCrossRef
85.
go back to reference Benbow SJ, Walsh A, Gill GV. Diabetes in the institutionalized elderly: a forgotten population? BMJ 1997; 315: 1868–70CrossRef Benbow SJ, Walsh A, Gill GV. Diabetes in the institutionalized elderly: a forgotten population? BMJ 1997; 315: 1868–70CrossRef
86.
go back to reference Tattersall R, Simon P. Managing diabetes in residential and nursing homes: presents a complex set of problems with no one solution. BMJ 1998; 316: 89PubMedCrossRef Tattersall R, Simon P. Managing diabetes in residential and nursing homes: presents a complex set of problems with no one solution. BMJ 1998; 316: 89PubMedCrossRef
87.
go back to reference Effects of intensive diabetes therapy on neuropsychological function in adults in the diabetes control and complications trial. Ann Intern Med 1996; 124: 379–88 Effects of intensive diabetes therapy on neuropsychological function in adults in the diabetes control and complications trial. Ann Intern Med 1996; 124: 379–88
88.
go back to reference Pramming S, Thorsteinsson B, Theilgaard A, et al. Cognitive function during hypoglycaemia in type I diabetes mellitus. BMJ 1986; 292: 647–50PubMedCrossRef Pramming S, Thorsteinsson B, Theilgaard A, et al. Cognitive function during hypoglycaemia in type I diabetes mellitus. BMJ 1986; 292: 647–50PubMedCrossRef
89.
go back to reference Fontbonne A, Berr C, Ducimetiere P. Poorer cognitive performance evolution over four years in elderly diabetics compared to controls with normal or impaired fasting blood glucose. Diabetes 2000; 49Suppl. 1: A191–2 Fontbonne A, Berr C, Ducimetiere P. Poorer cognitive performance evolution over four years in elderly diabetics compared to controls with normal or impaired fasting blood glucose. Diabetes 2000; 49Suppl. 1: A191–2
90.
go back to reference Davis SN, Shavers C, Davis B, et al. Prevention of an increase in plasma cortisol during hypoglycemia preserves subsequent counterregulatory responses. J Clin Invest 1997; 100: 429–38PubMedCrossRef Davis SN, Shavers C, Davis B, et al. Prevention of an increase in plasma cortisol during hypoglycemia preserves subsequent counterregulatory responses. J Clin Invest 1997; 100: 429–38PubMedCrossRef
91.
go back to reference Dagogo-Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 1994; 43: 1426–34PubMedCrossRef Dagogo-Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 1994; 43: 1426–34PubMedCrossRef
92.
go back to reference Cranston I, Lomas J, Maran A, et al. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 1994; 344: 283–7PubMedCrossRef Cranston I, Lomas J, Maran A, et al. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 1994; 344: 283–7PubMedCrossRef
93.
go back to reference Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23Suppl. 2: B21–9PubMed Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23Suppl. 2: B21–9PubMed
94.
go back to reference Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes: technical review. Diabetes Care 2003; 26: 1902–12PubMedCrossRef Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes: technical review. Diabetes Care 2003; 26: 1902–12PubMedCrossRef
Metadata
Title
Hypoglycaemia in Elderly Patients with Diabetes Mellitus
Causes and Strategies for Prevention
Authors
Aruna Chelliah
Dr Mark R. Burge
Publication date
01-07-2004
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 8/2004
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200421080-00003